Evidence map›Paper›PMID 35321782›Full record

ArticleBMB reports2022

SOCS1 counteracts ROS-mediated survival signals and promotes apoptosis by modulating cell cycle to increase radiosensitivity of colorectal cancer cells.

Ji-Yoon Ryu, Jiyoung Oh, Su-Min Kim, Won-Gi Kim, Hana Jeong, Shin-Ae Ahn, Seol-Hee Kim, Ji-Young Jang, Byong Chul Yoo, Chul Woo Kim and 1 more

Open access · greenAbstract readNews
In one paragraph

Article in BMB reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Ji-Yoon RyuLaboratory of Immunology, Department of Biological Science, College of Natural Science, Sungkyunkwan University, Suwon 16419, Korea.
Jiyoung OhLaboratory of Immunology, Department of Biological Science, College of Natural Science, Sungkyunkwan University, Suwon 16419, Korea.
Su-Min KimLaboratory of Immunology, Department of Biological Science, College of Natural Science, Sungkyunkwan University, Suwon 16419, Korea.
Won-Gi KimLaboratory of Immunology, Department of Biological Science, College of Natural Science, Sungkyunkwan University, Suwon 16419; Colorectal Cancer Branch, Research Center, National Cancer Institute, Goyang 10408, Korea.
Hana JeongLaboratory of Immunology, Department of Biological Science, College of Natural Science, Sungkyunkwan University, Suwon 16419, Korea.
Shin-Ae AhnLaboratory of Immunology, Department of Biological Science, College of Natural Science, Sungkyunkwan University, Suwon 16419, Korea.
Seol-Hee KimLaboratory of Immunology, Department of Biological Science, College of Natural Science, Sungkyunkwan University, Suwon 16419, Korea.
Ji-Young JangTumor Immunity Medical Research Center, Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080; Bioinfra Life Science Inc, Seoul 03127, Korea.
Byong Chul YooColorectal Cancer Branch, Research Center, National Cancer Institute, Goyang 10408, Korea.
Chul Woo KimTumor Immunity Medical Research Center, Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080; Bioinfra Life Science Inc, Seoul 03127, Korea.
Choong-Eun LeeLaboratory of Immunology, Department of Biological Science, College of Natural Science, Sungkyunkwan University, Suwon 16419, Korea.
Sungkyunkwan University · KRNational Cancer Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As negative regulators of cytokine signaling pathways, suppressors of cytokine signaling (SOCS) proteins have been reported to possess both pro-tumor and anti-tumor functions. Our recent studies have demonstrated suppressive effects of SOCS1 on epithelial to mesenchymal signaling in colorectal cancer cells in response to fractionated ionizing radiation or oxidative stress. The objective of the present study was to determine the radiosensitizing action of SOCS1 as an anti-tumor mechanism in colorectal cancer cell model. In HCT116 cells exposed to ionizing radiation, SOCS1 over-expression shifted cell cycle arrest from G2/M to G1 and promoted radiation-induced apoptosis in a p53-dependent manner with down-regulation of cyclin B and up-regulation of p21. On the other hand, SOCS1 knock-down resulted in a reduced apoptosis with a decrease in G1 arrest. The regulatory action of SOCS1 on the radiation response was mediated by inhibition of radiation-induced Jak3/STAT3 and Erk activities, thereby blocking G1 to S transition. Radiation-induced early ROS signal was responsible for the activation of Jak3/Erk/STAT3 that led to cell survival response. Our data collectively indicate that SOCS1 can promote radiosensitivity of colorectal cancer cells by counteracting ROS-mediated survival signal, thereby blocking cell cycle progression from G1 to S. The resulting increase in G1 arrest with p53 activation then contributes to the promotion of apoptotic response upon radiation. Thus, induction of SOCS1 expression may increase therapeutic efficacy of radiation in tumors with low SOCS1 levels. [BMB Reports 2022; 55(4): 198-203].

Indexed as

Colorectal NeoplasmsTumor Suppressor Protein p53ApoptosisCell CycleCell Line, TumorCytokinesHumansRadiation ToleranceReactive Oxygen SpeciesSuppressor of Cytokine Signaling 1 ProteinSuppressor of Cytokine Signaling ProteinsCytokinesReactive Oxygen SpeciesSOCS1 protein, humanSuppressor of Cytokine Signaling 1 ProteinSuppressor of Cytokine Signaling ProteinsTumor Suppressor Protein p53

Identifiers

PMID35321782
PMCPMC9058468
OpenAlexW4221162530

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.